Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 17.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Unternehmen & Branche
| Name | Kodiak Sciences Inc. |
|---|---|
| Ticker | KOD |
| CIK | 0001468748 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,42 Mrd. USD |
| Beta | 2,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -229,967,000 | -4.32 | 351,533,000 | 157,383,000 | |
| 2025-09-30 | 10-Q | -61,457,000 | -1.16 | 218,069,000 | 23,692,000 | |
| 2025-06-30 | 10-Q | -54,313,000 | -1.03 | 256,725,000 | 70,290,000 | |
| 2025-03-31 | 10-Q | -57,461,000 | -1.09 | 297,909,000 | 108,842,000 | |
| 2024-12-31 | 10-K | -176,207,000 | -3.35 | 335,578,000 | 150,288,000 | |
| 2024-09-30 | 10-Q | -43,946,000 | -0.84 | 372,669,000 | 185,370,000 | |
| 2024-06-30 | 10-Q | -45,117,000 | -0.86 | 401,578,000 | 214,506,000 | |
| 2024-03-31 | 10-Q | -43,039,000 | -0.82 | 434,759,000 | 241,189,000 | |
| 2023-12-31 | 10-K | -260,491,000 | -4.97 | 479,372,000 | 265,781,000 | |
| 2023-09-30 | 10-Q | -50,007,000 | -0.95 | 547,652,000 | 302,417,000 | |
| 2023-06-30 | 10-Q | -80,188,000 | -1.53 | 589,659,000 | 338,478,000 | |
| 2023-03-31 | 10-Q | -70,780,000 | -1.35 | 640,334,000 | 392,587,000 | |
| 2022-12-31 | 10-K | -333,823,000 | -6.39 | 666,628,000 | 436,167,000 | |
| 2022-09-30 | 10-Q | -77,038,000 | -1.47 | 723,988,000 | 479,529,000 | |
| 2022-06-30 | 10-Q | -90,628,000 | -1.74 | 781,905,000 | 530,931,000 | |
| 2022-03-31 | 10-Q | -95,709,000 | -1.83 | 850,288,000 | 597,384,000 | |
| 2021-12-31 | 10-K | -93,165,000 | -5.16 | 904,220,000 | 663,320,000 | |
| 2021-09-30 | 10-K | -67,526,000 | ||||
| 2021-09-30 | 10-Q | -67,526,000 | -1.30 | 958,206,000 | 726,320,000 | |
| 2021-06-30 | 10-K | -55,852,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | BORGESON JOHN A. | Officer, Chief Financial Officer | Open Market Sale | -600 | 41.77 | -25,062.00 | -0,3% | |
| 2026-04-02 | BORGESON JOHN A. | Officer, Chief Financial Officer | Open Market Sale | -4,231 | 40.88 | -172,963.28 | -2,0% | |
| 2026-04-02 | BORGESON JOHN A. | Officer, Chief Financial Officer | Open Market Sale | -12,477 | 40.29 | -502,698.33 | -5,7% | |
| 2026-04-02 | BORGESON JOHN A. | Officer, Chief Financial Officer | Open Market Sale | -12,692 | 39.14 | -496,764.88 | -5,7% | |
| 2025-12-18 | BAKER BROS. ADVISORS LP | Director, 10% Owner | Open Market Purchase | 217,428 | 23.00 | 5,000,844.00 | +57,2% | |
| 2025-12-18 | BAKER BROS. ADVISORS LP | Director, 10% Owner | Open Market Purchase | 2,391,268 | 23.00 | 54,999,164.00 | +629,1% | |
| 2025-06-17 | BORGESON JOHN A. | Officer, See Remarks | Open Market Sale | -723 | 3.65 | -2,639.67 | 0,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.